Stockscreener 앱 받기
4.27
4.26%
-0.19
시간 외 거래:
4.29
0.02
+0.47%
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Research Analysts Issue Forecasts for HURA Q2 Earnings - Defense World
TuHURA Biosciences’ Acquisition of Kineta - Global Legal Chronicle
Q2 Earnings Forecast for HURA Issued By Zacks Small Cap - MarketBeat
TuHURA Biosciences (HURA) Expected to Announce Earnings on Wednesday - MarketBeat
TuHURA Biosciences (HURA) Projected to Post Quarterly Earnings on Wednesday - Defense World
TuHURA Biosciences (NASDAQ:HURA) Stock Price Down 2.6%Here's Why - MarketBeat
TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened - Defense World
When Will TuHURA Biosciences, Inc. (NASDAQ:HURA) Turn A Profit? - Simply Wall St
When Can We Expect A Profit From TuHURA Biosciences, Inc. (NASDAQ:HURA)? - Yahoo Finance
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Purchases Shares of TuHURA Biosciences (NASDAQ:HURA) - Defense World
Rep. Laurel M. Lee Buys TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc.HURA - The Eastern Progress Online
TuHURA Biosciences appoints new accounting firm By Investing.com - Investing.com Australia
TuHURA Biosciences appoints new accounting firm - Investing.com India
TuHURA Biosciences (NASDAQ:HURA) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHYF, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
H.C. Wainwright sets $11 target on HURA with buy rating - Investing.com
Cancer Immunotherapy: TuHURA Biosciences to Acquire Kineta - orrick.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PDCO, ML, HURA, KANT on Behalf of Shareholders - Finansavisen
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ML, PDCO, HURA, KANT on Behalf of Shareholders - GlobeNewswire
TuHURA Biosciences, Inc. entered into a non-binding agreement to acquire Kineta, Inc. from Craig Philips and others for $30 million. - Marketscreener.com
TuHURA Biosciences to Acquire Kineta - citybiz
HURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of TuHURA Biosciences, Inc. Is Fair to Shareholders - The Bakersfield Californian
TuHURA Biosciences to Acquire Kineta, Inc. in 2025 - TipRanks
Kineta Merges with TuHURA to Enhance Cancer Treatment - TipRanks
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc. - Sacramento Bee
TuHURA to acquire Kineta in immunotherapy push - Investing.com
TuHURA to acquire Kineta in immunotherapy push By Investing.com - Investing.com UK
TuHURA Biosciences to Acquire Kineta, Adding Promising Phase 2 Cancer Immunotherapy to Pipeline - StockTitan
Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024 - The Eastern Progress Online
Stock market today: Unusual Machines +95.34%, VCI Global Limited +52.23% among top gainers in early trading - Business Upturn
TuHURA gears up for Phase 3 cancer trial in 2025 By Investing.com - Investing.com South Africa
Kineta and TuHURA Enter Acquisition Agreement - TipRanks
TuHURA Biosciences Advances in Cancer Immunotherapy Innovations - TipRanks
TuHURA gears up for Phase 3 cancer trial in 2025 - Investing.com
TuHURA Biosciences expects to complete enrollment for REM-001 study in Q4 - TipRanks
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell... - Markets Insider
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update - Eagle-Tribune
Rep. Laurel M. Lee TuHURA Biosciences (NASDAQ:HURA) Stock - Defense World
Rep. Laurel M. Lee TuHURA Biosciences (NASDAQ:HURA) Shares - MarketBeat
TuHURA Biosciences Announces Executive Salary and Stock Options - TipRanks
TuHURA Biosciences Inc (HURA) Quarterly 10-Q Report - Quartz
TuHURA Biosciences Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC - AccessWire
1.03%
자본화:
|
볼륨(24시간):